TKT to Report First Quarter Financial Results on April 27, 2004
22 4월 2004 - 4:56AM
PR Newswire (US)
TKT to Report First Quarter Financial Results on April 27, 2004
CAMBRIDGE, Mass., April 21 /PRNewswire-FirstCall/ -- Transkaryotic
Therapies, Inc. will report first quarter 2004 financial results on
Tuesday, April 27, 2004 before the open of U.S. financial markets.
In connection with this announcement, TKT will host a conference
call and live audio webcast on April 27, 2004 at 10:00 a.m. Eastern
Time. Participants may access the call by dialing (973) 317-5319.
This call will also be broadcast live over the Internet at
http://www.tktx.com/ under the Investor Information section. A
replay of this conference call will be available for two weeks,
beginning Tuesday, April 27, 2004 at 1:00 p.m. Eastern Time by
dialing (973) 709-2089 and using the access code 350896. In
addition, a replay of the webcast will be archived on the TKT
website in the Investor Information section. About TKT
Transkaryotic Therapies, Inc. is a biopharmaceutical company
primarily focused on researching, developing and commercializing
treatments for rare diseases caused by protein deficiencies. Within
this focus, the company markets Replagal(TM), an enzyme replacement
therapy for Fabry disease, and is developing treatments for Hunter
syndrome and Gaucher disease. Outside its focus on rare diseases,
TKT intends to commercialize Dynepo(TM), its Gene- Activated(R)
erythropoietin product for anemia related to kidney disease,
outside of the United States. TKT was founded in 1988 and is
headquartered in Cambridge, Massachusetts, with additional
operations in Europe, Canada and Latin America. Additional
information about TKT is available on the company's website at
http://www.tktx.com/. Gene-Activated(R) is a registered trademark
and Replagal(TM) is a trademark of Transkaryotic Therapies, Inc.
Dynepo(TM) is a trademark of Aventis Pharmaceuticals, Inc. CONTACT:
Daniella M. Lutz Corporate Communications Specialist (617) 349-0205
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
http://photoarchive.ap.org/ DATASOURCE: Transkaryotic Therapies,
Inc. CONTACT: Daniella M. Lutz, Corporate Communications Specialist
of Transkaryotic Therapies, Inc., +1-617-349-0205 Web site:
http://www.tktx.com/ Company News On-Call:
http://www.prnewswire.com/comp/120657.html
Copyright
Transkaryotic Therapies (NASDAQ:TKTX)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Transkaryotic Therapies (NASDAQ:TKTX)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Transkaryotic Therapies (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Transkaryotic (MM) News Articles